公开(公告)号：WO1996002260A1

公开(公告)日：1996-02-01

申请号：PCT/SE1995000875

申请日：1995-07-18

Applicant: MEDICARB AB ,  GOUDA, Ibrahim ,  LARM, Olle

Inventor： MEDICARB AB

IPC: A61K31/725

CPC classification number: A61K31/722 ,  A61K31/727 ,  A61L15/28 ,  A61L26/0023 ,  A61K2300/00 ,  C08L5/08

Abstract: The use of chitosan in combination with a first polysaccharide selected from heparin, heparan sulphate and dextran sulphate for the manufacture of an agent that accelerates, stimulates and/or promotes healing of dermal wounds, said polysaccharide, optionally, being immobilized to the chitosan; and a process for the treatment of dermal wounds.

Abstract translation: 壳聚糖与选自肝素，硫酸乙酰肝素和硫酸葡聚糖的第一多糖的组合用于制造加速，刺激和/或促进皮肤伤口愈合的药剂，所述多糖任选地固定在壳聚糖上; 以及用于治疗皮肤伤口的方法。

公开(公告)号：WO1996018423A1

公开(公告)日：1996-06-20

申请号：PCT/SE1995001459

申请日：1995-12-05

Applicant: MEDICARB AB ,  LARM, Olle ,  GOUDA, Ibrahim

Inventor： MEDICARB AB

IPC: A61L27/00

CPC classification number: A61L33/08 ,  A61F2/16 ,  A61L27/34 ,  A61L33/0029 ,  A61F2/14 ,  C08L79/00 ,  C08L5/10 ,  C08L5/08 ,  C08L5/00

Abstract: A process for the coating of an intraocular lens to impart tissue compatibility thereto, comprising the steps: a) priming said lens using a solution of a polyamine; b) coating the lens treated in step a) above with a solution of a periodate-oxidized polysaccharide selected from heparin, heparan sulphate, and chondroitin sulphate to stabilize said polyamine by covalent and/or ionical cross-linking; c) coating the lens treated in step b) above with a solution of a polyamine; and d) coating the lens treated according to step c) above with a solution of a periodate-oxidized polysaccharide selected from heparin, heparan sulphate, and chondroitin sulphate in the presence of a cyanoborohydride to convert formed labile Schiff's bases to stable secondary amines.

Abstract translation: 一种用于涂覆眼内透镜以赋予组织相容性的方法，包括以下步骤：a）使用多胺溶液引发所述镜片; b）用选自肝素，硫酸乙酰肝素和硫酸软骨素的高碘酸盐氧化多糖的溶液涂覆在上述步骤a）中处理的晶状体以通过共价和/或离子交联稳定所述多胺; c）用多胺溶液涂覆上述步骤b）中处理的晶状体; 和d）在氰基硼氢化钠存在下，用选自肝素，硫酸乙酰肝素和硫酸软骨素的高碘酸盐氧化多糖溶液涂覆根据上述步骤c）处理的晶状体，以将形成的不稳定希夫碱转化成稳定的仲胺。

公开(公告)号：WO1994016750A1

公开(公告)日：1994-08-04

申请号：PCT/SE1994000022

申请日：1994-01-14

Applicant: MEDICARB AB ,  GOUDA, Ibrahim ,  LARM, Olle

Inventor： MEDICARB AB

IPC: A61L33/00

CPC classification number: C08J7/047 ,  A61L27/34 ,  A61L33/0076 ,  C08J2403/00 ,  C08J2405/00 ,  C08L5/08

Abstract: A solid substrate, the surface of which has been modified to introduce reactive groups of a hydrophilic nature thereon, the modification being provided by a primer comprising a first polysaccharide containing as reactive groups amino and hydroxyl groups; and a process for the preparation of such solid substrate.

Abstract translation: 一种固体基质，其表面已经被修饰以在其上引入亲水性反应性基团，该修饰由包含含有作为反应性基团的第一多糖的引物包含氨基和羟基的引物提供; 以及制备这种固体基质的方法。

公开(公告)号：WO1998005341A1

公开(公告)日：1998-02-12

申请号：PCT/SE1997001320

申请日：1997-08-01

Applicant: MEDICARB AB ,  LARM, Olle ,  BACK, Marcus ,  BERGSTRÖM, Tomas

Inventor： MEDICARB AB

IPC: A61K31/725

CPC classification number: A61K45/06 ,  A61K31/715

Abstract: The use of heparin or heparan sulphate in combination with chitosan for the manufacture of a medicament for the prevention or treatment of infections caused by herpes virus in mammal including man; and a process for the treatment of infectious diseases caused by herpes viruses.

Abstract translation: 使用肝素或硫酸乙酰肝素与壳聚糖组合用于制备用于预防或治疗由哺乳动物包括人在内的疱疹病毒引起的感染的药物; 以及治疗由疱疹病毒引起的传染病的过程。

公开(公告)号：WO1994016714A1

公开(公告)日：1994-08-04

申请号：PCT/SE1994000021

申请日：1994-01-14

Applicant: MEDICARB AB ,  LARM, Olle ,  WADSTRÖM, Torkel

Inventor： MEDICARB AB

IPC: A61K31/725

CPC classification number: A61K31/715

Abstract: The use of a composition in the preparation of a drug for the treatment or prophylaxis of infections caused by or associated with Helicobacter pylori, said composition containing as an active constituent an immobilized, negatively charged polysaccharide selected from the group comprising: heparin, heparan sulphate and dextran sulphate; a method of treating or preventing infections caused by or associated with Helicobacter pylori in mammals including man, comprising administering to a mammal in need of such treatment or prophylaxis an effective amount of a composition containing as an active constituent an immobilized, negatively charged polysaccharide selected from the group comprising: heparin, heparan sulphate and dextran sulphate; a protein with an apparent molecular weight of not more than about 120 kDa (on SDS-PAGE) and active subfragments thereof down to a molecular weight of about 20 kDa, said protein and subfragments specifically binding to heparan sulphate and being producible from H. pylori strains 25 and 1139 as a surface protein antigen thereof; mono- and polyclonal antibodies; process for detecting H. pylori; drug compositions; reagent kit; and a vaccine.

Abstract translation: 在制备用于治疗或预防由幽门螺杆菌引起或与幽门螺杆菌有关的感染的药物中的组合物的用途，所述组合物含有作为活性成分的固定化带负电荷的多糖，其选自肝素，硫酸乙酰肝素和 硫酸葡聚糖; 治疗或预防包括人在内的哺乳动物中由幽门螺杆菌引起或与幽门螺杆菌有关的感染的方法，包括向需要这种治疗或预​​防有效量的含有作为活性成分的组合物施用有效量的选自以下的固定化带负电荷的多糖的组合物： 该组包括：肝素，硫酸乙酰肝素和硫酸葡聚糖; 具有表达分子量不超过约120kDa的蛋白质（在SDS-PAGE上）及其活性亚片段分子量约为20kDa，所述蛋白质和亚片段特异性结合硫酸肝素并且可从幽门螺杆菌 菌株25和1139作为其表面蛋白抗原; 单克隆和多克隆抗体; 检测幽门螺杆菌的过程; 药物组成; 试剂盒; 和疫苗。

公开(公告)号：WO1988004303A1

公开(公告)日：1988-06-16

申请号：PCT/SE1987000577

申请日：1987-12-03

Applicant: MEDICARB AB

Inventor： MEDICARB AB ,  BROWN, Robert, George ,  GILL, Sikander, Singh

IPC: C07K15/08

CPC classification number: G01N33/56916 ,  A61K38/00 ,  C07K14/435 ,  G01N2400/50

Abstract: A method for manufacturing scallop lectin, which comprises: a) extracting a lectin-containing product from the digestive glands of a scallop selected from the family Pectinidae and the genus Haliotis, and b) purifying the resulting lectin-containing extract; and a lectin-haemagglutinin extracted from the digestive gland of a scallop selected from the family Pectinidae and the genus Haliotis, such as Placopecten magellanicus and possessing activity against Gram-negative bacteria, characterized by: a) a molecular weight of from about 10.000 to 20.000 under denaturing conditions; b) an ability to agglutinate sheep erythrocytes; c) an ability to agglutinate picoplankton of the species Spinobacter and Synechococcus; d) marked agglutination ability with respect to Gram-negative bacteria of the species Agrobacterium tumefaciens, Escherichia coli and Serratia marcescens; e) an isoelectric point in the range of about pH 4-5; and f) resistance to the proteolytic enzymes proteinase K, pronase and trypsin.

Abstract translation: 一种扇贝凝集素的制造方法，其特征在于，包括：a）从选自茄科和Haliotis的扇贝的消化腺中提取含凝集素的产品，b）纯化得到的凝集素提取物; 以及从选自禾本科和Haliotis属的扇贝的消化腺提取的凝集素血凝素，例如麦角菌（Placopecten magellanicus），并且具有抗革兰氏阴性菌的活性，其特征在于：a）分子量为约10.000至20.000 在变性条件下; b）凝集羊红细胞的能力; c）将螺旋杆菌和聚球细菌物种的浮游生物凝集的能力; d）对根癌土壤杆菌，大肠杆菌和粘质沙雷氏菌物种的革兰氏阴性细菌具有明显的凝集能力; e）约pH 4-5的等电点; 和f）对蛋白水解酶蛋白酶K，链霉蛋白酶和胰蛋白酶的抗性。